SPY391.21+3.71 0.96%
DIA319.33+3.94 1.25%
IXIC13,544.98+79.79 0.59%

Research Alert: CFRA Retains Buy Opinion On Shares Of Johnson & Johnson

· 02/04/2021 19:46

12:45 AM EST, 02/05/2021 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

JNJ announced yesterday after market close that it has submitted an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration for its single-dose Covid-19 vaccine. This follows the release of the efficacy and safety data from the Phase 3 clinical trials last week, which pointed to a 66% overall efficacy rate for the vaccine. Although JNJ's vaccine efficacy is lower compared to mRNA-based vaccines of Pfizer-BioNTech and Moderna, JNJ's single-dose regimen and much less complex storage requirements are critical advantages, in our view. If the EUA were to be granted in a few weeks, similar to the time it took for Pfizer-BioNTech and Moderna after their applications, we think JNJ's vaccine might be a key differentiator to accelerate the vaccination campaign in the U.S. JNJ has an agreement with the U.S. government to provide 100 million doses once authorized, with an option to supply additional 200 million doses.